Manjunatha S. Katagi

Dr. Manjunatha S. Katagi

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Journal of Molecular Structure
Verified
Journal Article
Closed access
GBGirish Bolakatti
Girish Bolakatti
MPMahesh Palkar
Mahesh Palkar
MKManjunatha S. Katagi
Manjunatha S. Katagi
GHGirish Hampannavar
Girish Hampannavar
RKRajshekhar V. Karpoormath
Rajshekhar V. Karpoormath
ABArvind Badiger
Arvind Badiger

17 July 2023 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
SLSujatha M. L
Sujatha M. L
BNBelakatte P. Nandeshwarappa
Belakatte P. Nandeshwarappa
MKManjunatha S. Katagi
Manjunatha S. Katagi
Alzheimer’s disease (AD), an ongoing neurodegenerative disorder among the elderly, is signalized by amnesia, progressive deficiency in cognitive roles, and behavioral deformity. Over the last ten years, its pathogenesis still remains unclear despite several efforts from various researchers across the globe. There are certain factors that seem to be involved in the progression of the disease such as the accumulation of β-amyloid, oxidative stress, the hyperphosphorylation of tau protein, and a deficit of acetylcholine (ACh). Ongoing therapeutics are mainly based on the cholinergic hypothesis, which suggests that the decrease in the ACh levels leads to the loss of memory. Therefore, increasing the cholinergic function seems to be beneficial. Acetylcholinesterase inhibitors (AChEIs) inhibit the enzyme by avoiding the cleavage of acetylcholine (ACh) and increasing the neurotransmitter acetylcholine (ACh) levels in the brain areas. Thus, the cholinergic deficit is the root cause of Alzheimer’s disease (AD). Currently, drugs such as tacrine, donepezil, rivastigmine, and galantamine have been launched on the market for a cholinergic approach to AD to increase neurotransmission at cholinergic synapses in the brain and to improve cognition. These commercialized medicines only provide supportive care, and there is a loss of medicinal strength over time. Therefore, there is a demand for investigating a novel molecule that overcomes the drawbacks of commercially available drugs. Therefore, butyrylcholinesterase (BChE), amyloid-β (Aβ), β-secretase-1 (BACE), metals Cu(II), Zn(II), or Fe(II), antioxidant properties, and the free radical scavenging capacity have been primarily targeted in the preceding five years along with targeting the AChE enzyme. A desired, well-established pharmacological profile with a number of hybrid molecules incorporating substructures within a single scaffold has been investigated. From distinct chemical categories such as acridine, quinoline, carbamate, huperzine, and other heterocyclic analogs, the main substructures used in developing these molecules are derived. The optimization of activity through structural modifications of the prototype molecules has been followed to develop the Structure Activity Relationship (SAR), which in turn facilitates the development of novel molecules with expected AChE inhibitory activity together with many more pharmacological properties. The present review outlines the current drug candidates in the advancement of these AChEIs in the last two years.

14 April 2025 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
SLSujatha M. L
Sujatha M. L
MKManjunatha S. Katagi
Manjunatha S. Katagi
GBGirish S. Bolakatti
Girish S. Bolakatti
JSJohnson Samuel
Johnson Samuel
BNBelakatte P. Nandeshwarappa
Belakatte P. Nandeshwarappa
Background: The cholinergic hypothesis is an elementary approach employed for the research and drug discovery of novel anti-Alzheimer therapeutics. Method: In this context, the study focuses on synthesizing and evaluating a new series of chalcone derivatives (3a–3j) as multifunctional therapeutic agents, specifically investigating their antioxidant potential using the DPPH method with ascorbic acid as a standard. Ellman’s protocol for acetylcholinesterase inhibition assay was performed using donepezil as a standard, and computational insights were explored through molecular docking and ADME profiling. Results: Compounds 3a, 3d, 3e, 3f, and 3h exhibited excellent antioxidant activity compared to the standard. Most of the compounds exhibited moderate to good (3b, 3c, and 3h) AChE inhibitory activity. Molecular docking studies revealed conventional hydrogen bonding and π-π interactions with the enzyme’s active residues, facilitated by their electronegative groups and phenyl rings, respectively. In addition, a pharmacokinetic study was conducted using computational approach to assess druggability. The results demonstrated that compound 3b is an outstanding lead candidate with appreciable AChE inhibitory activity. Conclusions: The combined experimental and computational results of this study highlight the multifunctional nature of chalcone derivatives, suggesting their potential as promising therapeutic agents for the discovery of novel AChE inhibitors that could be employed in the management of Alzheimer’s disease and oxidative stress-related diseases.

31 October 2025 in Russian Journal of General Chemistry
Verified
Journal Article
Closed access
PDF file
MKManjunatha S. Katagi
Manjunatha S. Katagi
DRD. K. Ramesh
D. K. Ramesh
MSM. L. Sujatha
M. L. Sujatha
BNB. P. Nandeshwarappa
B. P. Nandeshwarappa
SDS. M. Desai
S. M. Desai
GPG. S. Prathibha
G. S. Prathibha
The present work deals with synthesis, characterization and in vitro reactivation of chlorpyrifos inhibited acetylcholinesterase by 3-[(1E,14Z)-3-(4-aryl)-3-(hydroxyimino)prop-1-enyl]-1-methylquinolin-2(1H)-one derivatives. Synthetic strategy involving the condensation of 1,2-dihydro-1-methyl-2-oxoquinoline-3-carbaldehydewith substituted acetophenones in presence of piperidine and ethanol as a solvent afford a series of chalcones with good yield. The title compounds were prepared by the condensation of the chalcones with hydroxylamine hydrochloride in ethanol and pyridine as a base. The structures of all the newly synthesized products were confirmed with their elemental analysis, IR, 1H NMR, 13C NMR and mass spectral analysis. All the newly synthesized compounds were screened for their reactivation efficacy against chlorpyrifos inhibited electric eel AChE by Ellman’s method. The data reveal that all the newly developed reactivators could not reactivate chlorpyrifos-inhibited AChE. Only two compounds of chalcone oxime, p-amino and p-nitro were found to be moderate reactivators as compared to standard.

31 December 2025 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
SLSujatha M. L
Sujatha M. L
MKManjunatha S. Katagi
Manjunatha S. Katagi
GBGirish S. Bolakatti
Girish S. Bolakatti
JSJohnson Samuel
Johnson Samuel
BNBelakatte P. Nandeshwarappa
Belakatte P. Nandeshwarappa
The journal retracts the article titled “Exploring Chalcone Derivatives as a Multifunctional Therapeutic Agent: Investigating Antioxidant Potential, Acetylcholinesterase Inhibition and Computational Insights”

1 January 2020 in Rajiv Gandhi University of Health Sciences Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
BNBp Nandeshwarappa
Bp Nandeshwarappa
MKManjunatha S. Katagi
Manjunatha S. Katagi
DRDk Ramesh
Dk Ramesh
MSM Suchitra
M Suchitra
SSSo Sadashiv
So Sadashiv
Background The design of new agents active against resistant organism is of critical importance. The current antimicrobial chemotherapy still suffers from two major limitations. The first is the lack of selectivity of conventional antimicrobial agents which in turn brings about unwanted side effects. The second is acquisitions by the microorganism of multi drug resistance.Objective To synthesize a series of quinoline-2-one linked thiadiazole derivatives and to asses in vitro antimicrobial activity.Method The derivatives of quinoline-2-one linked thiadiazole were synthesized purified and characterized on the basis of physiochemical and spectral studies. The synthesized compounds were subjected for in vitro antimicrobial activity by cup-plate agar diffusion.Results Among the eight synthesized novel compounds three compounds 4b 4c and 4f shows promising antibacterial activity as compared to Ciprofloxacin 100 microgml however most of them 4b 4c 4e and 4f showed potent antifungal activity as compared to Fluconazole 100 microgml.Conclusion Despite continued efforts to discover improved antimicrobial agents there has been little success towards discover of antimicrobial agents. The compounds having fluoro substitution at 4th amp 24-dichloro positions showed satisfactory antibacterial and antifungal activity.nbsp